神经性疼痛的个性化疗效:一项随机对照试验的临床相关性和检测敏感性分析。

IF 2.9 3区 医学 Q1 ANESTHESIOLOGY Pain Medicine Pub Date : 2024-10-04 DOI:10.1093/pm/pnae095
Karim Saab, Umang Gada, Eva Culakova, Brian Burnette, Carla Jorgensen, Dhaval Shah, Gary Morrow, Karen Mustian, Michael B Sohn, Robert R Edwards, Roy Freeman, Dale J Langford, Michael P McDermott, Jennifer S Gewandter
{"title":"神经性疼痛的个性化疗效:一项随机对照试验的临床相关性和检测敏感性分析。","authors":"Karim Saab, Umang Gada, Eva Culakova, Brian Burnette, Carla Jorgensen, Dhaval Shah, Gary Morrow, Karen Mustian, Michael B Sohn, Robert R Edwards, Roy Freeman, Dale J Langford, Michael P McDermott, Jennifer S Gewandter","doi":"10.1093/pm/pnae095","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To explore the clinical relevance and assay sensitivity of using personalized outcomes using data from a randomized clinical trial (RCT) in people with chemotherapy induced peripheral neuropathy (CIPN).</p><p><strong>Design: </strong>This study is a secondary analysis that leveraged data from a RCT of transcutaneous electrical stimulation for CIPN to test whether personalized outcomes could minimize potential floor effects and increase the assay sensitivity of pain clinical trials (ie, ability to detect a true treatment effect).</p><p><strong>Setting: </strong>Participants were recruited for a RCT from community oncology clinics in the U.S.</p><p><strong>Participants: </strong>Adults with CIPN (N = 72) who reported on average ≥4 intensity (measured via a 7-day baseline diary) for at least one of the following pain qualities hot/burning pain, sharp/shooting pain and/or cramping.</p><p><strong>Methods: </strong>Personalized outcomes were defined based on participants' unique presentation of pain qualities at baseline, measured via 0-10 numeric rating scales (NRS), or ranking of the distress caused by the pain qualities. Analysis of covariance models estimated the treatment effect as measured by personalized and non-personalized outcomes.</p><p><strong>Results: </strong>The adjusted mean difference between groups was higher using personalized outcomes (ie, 1.21-1.25 NRS points) compared to a non-personalized outcome (ie, 0.97 NRS points), although the standardized effect sizes were similar between outcomes (0.49-0.54).</p><p><strong>Conclusions: </strong>These results suggest that personalized pain quality outcomes could minimize floor effects, while providing similar assay sensitivity to non-personalized pain quality outcomes. Personalized outcomes better reflect an individual's unique experience, inherently providing more clinically relevant estimates of treatment effects. Personalized outcomes may be advantageous particularly for clinical trials in populations with high inter-individual variability in pain qualities.</p>","PeriodicalId":19744,"journal":{"name":"Pain Medicine","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Personalized Outcomes in Neuropathic Pain: A Clinical Relevance and Assay Sensitivity Analysis from a Randomized Controlled Trial.\",\"authors\":\"Karim Saab, Umang Gada, Eva Culakova, Brian Burnette, Carla Jorgensen, Dhaval Shah, Gary Morrow, Karen Mustian, Michael B Sohn, Robert R Edwards, Roy Freeman, Dale J Langford, Michael P McDermott, Jennifer S Gewandter\",\"doi\":\"10.1093/pm/pnae095\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To explore the clinical relevance and assay sensitivity of using personalized outcomes using data from a randomized clinical trial (RCT) in people with chemotherapy induced peripheral neuropathy (CIPN).</p><p><strong>Design: </strong>This study is a secondary analysis that leveraged data from a RCT of transcutaneous electrical stimulation for CIPN to test whether personalized outcomes could minimize potential floor effects and increase the assay sensitivity of pain clinical trials (ie, ability to detect a true treatment effect).</p><p><strong>Setting: </strong>Participants were recruited for a RCT from community oncology clinics in the U.S.</p><p><strong>Participants: </strong>Adults with CIPN (N = 72) who reported on average ≥4 intensity (measured via a 7-day baseline diary) for at least one of the following pain qualities hot/burning pain, sharp/shooting pain and/or cramping.</p><p><strong>Methods: </strong>Personalized outcomes were defined based on participants' unique presentation of pain qualities at baseline, measured via 0-10 numeric rating scales (NRS), or ranking of the distress caused by the pain qualities. Analysis of covariance models estimated the treatment effect as measured by personalized and non-personalized outcomes.</p><p><strong>Results: </strong>The adjusted mean difference between groups was higher using personalized outcomes (ie, 1.21-1.25 NRS points) compared to a non-personalized outcome (ie, 0.97 NRS points), although the standardized effect sizes were similar between outcomes (0.49-0.54).</p><p><strong>Conclusions: </strong>These results suggest that personalized pain quality outcomes could minimize floor effects, while providing similar assay sensitivity to non-personalized pain quality outcomes. Personalized outcomes better reflect an individual's unique experience, inherently providing more clinically relevant estimates of treatment effects. Personalized outcomes may be advantageous particularly for clinical trials in populations with high inter-individual variability in pain qualities.</p>\",\"PeriodicalId\":19744,\"journal\":{\"name\":\"Pain Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-10-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pain Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/pm/pnae095\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ANESTHESIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pain Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/pm/pnae095","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的利用针对化疗诱发周围神经病变(CIPN)患者的随机临床试验(RCT)数据,探讨使用个性化结果的临床相关性和检测灵敏度:本研究是一项二次分析,利用经皮电刺激治疗 CIPN 的 RCT 数据,测试个性化结果是否能最大限度地减少潜在的底线效应,并提高疼痛临床试验的检测灵敏度(即检测真实治疗效果的能力):参与者:从美国社区肿瘤诊所招募的 RCT 参与者:成人 CIPN 患者(72 人),他们报告的平均疼痛强度≥4 级(通过 7 天基线日记测量),至少具有以下一种疼痛特质:热痛/灼痛、剧痛/针刺痛和/或绞痛:个性化结果是根据参与者在基线时对疼痛特质的独特表现(通过 0-10 数字评分量表(NRS)测量)或疼痛特质造成的痛苦程度排名来定义的。协方差分析模型估算了通过个性化和非个性化结果衡量的治疗效果:结果:与非个性化结果(即 0.97 个 NRS 点)相比,使用个性化结果(即 1.21-1.25 个 NRS 点)的组间调整后平均差异更高,尽管不同结果的标准化效应大小相似(0.49-0.54):这些结果表明,个性化疼痛质量结果可以最大限度地减少最低效应,同时提供与非个性化疼痛质量结果相似的检测灵敏度。个性化结果能更好地反映个体的独特体验,从而提供与临床更相关的治疗效果估计值。对于疼痛质量个体间差异较大的人群,个性化结果可能更有利于临床试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Personalized Outcomes in Neuropathic Pain: A Clinical Relevance and Assay Sensitivity Analysis from a Randomized Controlled Trial.

Objective: To explore the clinical relevance and assay sensitivity of using personalized outcomes using data from a randomized clinical trial (RCT) in people with chemotherapy induced peripheral neuropathy (CIPN).

Design: This study is a secondary analysis that leveraged data from a RCT of transcutaneous electrical stimulation for CIPN to test whether personalized outcomes could minimize potential floor effects and increase the assay sensitivity of pain clinical trials (ie, ability to detect a true treatment effect).

Setting: Participants were recruited for a RCT from community oncology clinics in the U.S.

Participants: Adults with CIPN (N = 72) who reported on average ≥4 intensity (measured via a 7-day baseline diary) for at least one of the following pain qualities hot/burning pain, sharp/shooting pain and/or cramping.

Methods: Personalized outcomes were defined based on participants' unique presentation of pain qualities at baseline, measured via 0-10 numeric rating scales (NRS), or ranking of the distress caused by the pain qualities. Analysis of covariance models estimated the treatment effect as measured by personalized and non-personalized outcomes.

Results: The adjusted mean difference between groups was higher using personalized outcomes (ie, 1.21-1.25 NRS points) compared to a non-personalized outcome (ie, 0.97 NRS points), although the standardized effect sizes were similar between outcomes (0.49-0.54).

Conclusions: These results suggest that personalized pain quality outcomes could minimize floor effects, while providing similar assay sensitivity to non-personalized pain quality outcomes. Personalized outcomes better reflect an individual's unique experience, inherently providing more clinically relevant estimates of treatment effects. Personalized outcomes may be advantageous particularly for clinical trials in populations with high inter-individual variability in pain qualities.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Pain Medicine
Pain Medicine 医学-医学:内科
CiteScore
6.50
自引率
3.20%
发文量
187
审稿时长
3 months
期刊介绍: Pain Medicine is a multi-disciplinary journal dedicated to pain clinicians, educators and researchers with an interest in pain from various medical specialties such as pain medicine, anaesthesiology, family practice, internal medicine, neurology, neurological surgery, orthopaedic spine surgery, psychiatry, and rehabilitation medicine as well as related health disciplines such as psychology, neuroscience, nursing, nurse practitioner, physical therapy, and integrative health.
期刊最新文献
Evaluation of a novel nerve ablation technique to relieve lower back pain: A cadaveric feasibility pilot study. Single Arm Feasibility Trial of a Mobile Application for Adolescent Migraine Management. The NIH Pain Common Data Elements: A Great Start but a Long Way to the Finish Line. Effectiveness of fremanezumab treatment in patients with migraine headache. Varying definitions of long-term opioid therapy: examining prevalence, prescription patterns, and substance-related adverse outcomes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1